| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_66bf9241573049a8f547817507011e90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_de7c1a8154681def36fc24277647ce75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb72e002ed2d606901981aa74e5db187
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3eaed70713265977c5c4d4c5b51efe07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a33c2b4ed2ad40fef7bf9029b51dac1c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2012-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef4a59ab02230876239ea264e2be964f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f14a317cee298b820cefe0d13aa55f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba53d81428d582888c9b51133b7ac60a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1101dc66662e99e7b8b590df4b11aff |
| publicationDate |
2017-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9561174-B2 |
| titleOfInvention |
Ibuprofen for topical administration |
| abstract |
Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl) propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11007161-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018213071-A1 |
| priorityDate |
2008-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |